These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21397482

  • 21. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 22. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 23. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 24. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG.
    Respir Med; 2013 Jun 22; 107(6):848-53. PubMed ID: 23490225
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 22; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb 22; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.
    Pulm Pharmacol Ther; 2009 Dec 22; 22(6):492-6. PubMed ID: 19465142
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
    Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P.
    Respir Res; 2013 Oct 07; 14(1):100. PubMed ID: 24093477
    [Abstract] [Full Text] [Related]

  • 33. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, INTRUST-1 and INTRUST-2 study investigators.
    Thorax; 2012 Sep 07; 67(9):781-8. PubMed ID: 22544891
    [Abstract] [Full Text] [Related]

  • 34. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J, Akitsu K.
    Pulm Pharmacol Ther; 2015 Feb 07; 30():128-33. PubMed ID: 25183687
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
    Karner C, Cates CJ.
    Cochrane Database Syst Rev; 2012 Apr 18; 4(4):CD008989. PubMed ID: 22513969
    [Abstract] [Full Text] [Related]

  • 39. Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.
    Kim JS, Park J, Lim SY, Oh YM, Yoo KH, Park YB, Sheen SS, Kim MJ, Carriere KC, Jung JY, Park HY.
    PLoS One; 2015 Apr 18; 10(3):e0119948. PubMed ID: 25799171
    [Abstract] [Full Text] [Related]

  • 40. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP, Hanania NA, McGinty J, Denis-Mize K, Chaudry I.
    Adv Ther; 2009 Nov 18; 26(11):1024-34. PubMed ID: 19953349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.